{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:42:19Z","timestamp":1773027739380,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2635-0","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T05:18:22Z","timestamp":1470115102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants"],"prefix":"10.1186","volume":"16","author":[{"given":"Simona","family":"Soverini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"De Benedittis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana","family":"Bavaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Machova Polakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Linhartova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"2635_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2217\/pgs.12.103","volume":"13","author":"S Soverini","year":"2012","unstructured":"Soverini S, Martinelli G, Rosti G, Iacobucci I, Baccarani M. Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. Pharmacogenomics. 2012;13:1271\u201384.","journal-title":"Pharmacogenomics"},{"key":"2635_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200\u20136.","journal-title":"Leukemia"},{"key":"2635_CR3","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1002\/cncr.24504","volume":"115","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Pasquini R, Levy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009;115:4136\u201347.","journal-title":"Cancer"},{"key":"2635_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141\u20135.","journal-title":"Blood"},{"key":"2635_CR5","doi-asserted-by":"publisher","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","volume":"65","author":"DJ Barnes","year":"2005","unstructured":"Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005;65:8912\u20139.","journal-title":"Cancer Res"},{"key":"2635_CR6","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371","volume":"86","author":"A Gaiger","year":"1995","unstructured":"Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, Greinix H, Mannhalter C, Haas OA, Lechner K, et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995;86:2371\u20138.","journal-title":"Blood"},{"key":"2635_CR7","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/leu.2010.101","volume":"24","author":"M Marega","year":"2010","unstructured":"Marega M, Piazza RG, Pirola A, Redaelli S, Mogavero A, Iacobucci I, Meneghetti I, Parma M, Pogliani EM, Gambacorti-Passerini C. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients. Leukemia. 2010;24:1445\u20139.","journal-title":"Leukemia"},{"key":"2635_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell. 2005;8:355\u201368.","journal-title":"Cancer Cell"},{"key":"2635_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1182\/blood-2007-03-078303","volume":"110","author":"JS Chang","year":"2007","unstructured":"Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, et al. High levels of the BCR\/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C\/EBPalpha-driven myeloid differentiation. Blood. 2007;110:994\u20131003.","journal-title":"Blood"},{"key":"2635_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11899-012-0114-5","volume":"7","author":"T Skorski","year":"2012","unstructured":"Skorski T. Genetic mechanisms of chronic myeloid leukemia blastic transformation. Curr Hematol Malig Rep. 2012;7:87\u201393.","journal-title":"Curr Hematol Malig Rep"},{"key":"2635_CR11","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","volume":"93","author":"R Hehlmann","year":"2008","unstructured":"Hehlmann R, Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica. 2008;93:1765\u20139.","journal-title":"Haematologica"},{"key":"2635_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2009.006999","volume":"94","author":"RT Silver","year":"2009","unstructured":"Silver RT, Cortes J, Waltzman R, Mone M, Kantarjian H. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009;94:743\u20134.","journal-title":"Haematologica"},{"key":"2635_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","volume":"38","author":"S Soverini","year":"2014","unstructured":"Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Muller MC, Radich JP, Shah NP. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38:10\u201320.","journal-title":"Leuk Res"},{"key":"2635_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26:428\u201342.","journal-title":"Cancer Cell"},{"key":"2635_CR15","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1073\/pnas.1321173111","volume":"111","author":"DL Gibbons","year":"2014","unstructured":"Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, Talpaz M, Donato N, Quintas-Cardama A. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A. 2014;111:3550\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2635_CR16","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","volume":"122","author":"S Soverini","year":"2013","unstructured":"Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122:1634\u201348.","journal-title":"Blood"},{"key":"2635_CR17","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","volume":"141","author":"K Machova Polakova","year":"2015","unstructured":"Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, Martinelli G, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141:887\u201399.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2635_CR18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Muller MC, Ernst T, Rosti G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208\u201315.","journal-title":"Blood"},{"key":"2635_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ajh.22272","volume":"87","author":"M Alikian","year":"2012","unstructured":"Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, et al. BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol. 2012;87:298\u2013304.","journal-title":"Am J Hematol"},{"key":"2635_CR20","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2015.152","volume":"29","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823\u201331.","journal-title":"Leukemia"},{"key":"2635_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28\u201337.","journal-title":"Blood"},{"key":"2635_CR22","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","volume":"50","author":"S Soverini","year":"2004","unstructured":"Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G, Pane F, Saglio G, Baccarani M. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004;50:1205\u201313.","journal-title":"Clin Chem"},{"key":"2635_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.10822","volume":"92","author":"S Soverini","year":"2007","unstructured":"Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007;92:401\u20134.","journal-title":"Haematologica"},{"key":"2635_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2635_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.leukres.2014.10.005","volume":"39","author":"JH Lipton","year":"2015","unstructured":"Lipton JH, Bryden P, Sidhu MK, Huang H, McGarry LJ, Lustgarten S, Mealing S, Woods B, Whelan J, Hawkins N. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res. 2015;39:58\u201364.","journal-title":"Leuk Res"},{"key":"2635_CR26","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","volume":"114","author":"RJ Garg","year":"2009","unstructured":"Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114:4361\u20138.","journal-title":"Blood"},{"key":"2635_CR27","doi-asserted-by":"crossref","unstructured":"Soverini S, De Benedittis C, Machova Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M et al: Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget. 2016; in press.","DOI":"10.18632\/oncotarget.8010"},{"key":"2635_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.13966","volume":"173","author":"S Soverini","year":"2016","unstructured":"Soverini S, De Benedittis C, Mancini M, Martinelli G. Present and future of molecular monitoring in chronic myeloid leukaemia. Br J Haematol. 2016;173:337\u201349.","journal-title":"Br J Haematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2635-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2635-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2635-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2635-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T17:12:43Z","timestamp":1600967563000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2635-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2635"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2635-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]},"article-number":"572"}}